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Abstract
Objective
To assess long term safety of extended repeated 3-month courses of ulipristal acetate (UPA)
10 mg/day, for up to 8 courses, with focus on endometrial and laboratory safety parameters.
Methods
This long-term, multi-center, open-label cohort, follow up study consisted of up to 8 conse-
cutive 3-month courses of daily UPA 10 mg, each separated by a drug free period of 2 spon-
taneous menstrual bleeds. Sixty-four pre-menopausal women, with moderate to severe
symptomatic uterine myoma(s) and heavy bleeding were enrolled and were studied for
approximately 4 years. The main outcome measures were endometrial histology, laboratory
parameters and general safety.
Results
All data was reported in a descriptive manner with no formal statistical comparisons. In the 64
women, non-physiological changes (mostly cyst formation, epithelial and vascular changes)
in endometrial histology at screening and after treatment courses 4 and 8 were observed in
18.0%, 21.4% and 16.3% of biopsies, respectively. After treatment cessation, such changes
were observed in 9.1% of biopsies. All endometrial biopsies were benign after course 8. The
median endometrial thickness was 7.0 mm, 10–18 days after the start of menses following
treatment courses 5–8, compared to 9.0 mm at screening (before UPA treatment). No
changes in the number and type of laboratory results outside the normal ranges were
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observed with the increasing treatment courses. In total, adverse events were reported in
10 (16%), 12 (19%), 8 (14%) and 5 (9%) subjects, during treatment courses 5, 6, 7 and 8,
respectively of which the most frequent adverse events were headache and hot flush.
Conclusion
The results of this study further support the safety profile of extended repeated 3 months
treatment of symptomatic fibroids with ulipristal acetate 10 mg/day. Repeated UPA treat-
ment courses did not result in any changes of concern in endometrial histology, endometrial
thickness, or laboratory safety measures.
Introduction
Selective progesterone receptor modulators (SPRMs) offer novel and unique medical treat-
ment options in gynecology [1] and the potential of SPRM for the treatment of uterine fibroids
has been well established [2]. Ulipristal acetate (UPA) represents a SPRM which has been dem-
onstrated to effectively control excessive bleeding due to uterine fibroids and may lead to
fibroid shrinkage [3] [4]. After treatment cessation, this reduction in fibroid volume may be
sustained for up to 6 months [3] [4] with menstruation usually returning within 4 weeks. In
addition, treatment with UPA corrects hemoglobin and hematocrit levels, reduces fibroid-
associated pain and improves quality of life [3] [4].
SPRMs demonstrate predominant anti-progesterone activity and their administration can
lead to a pattern of benign, non-physiological, endometrial histological features referred to as
Progesterone receptor modulator Associated Endometrial Changes (PAEC). These changes
are characterized by cystic glandular dilatation, apoptosis, low mitotic activity in the glands
and stroma, absence of stromal breakdown, and glandular crowding [5] [6]. The histological
diagnosis of PAEC is made by the observation of simultaneous presence of a variable range of
non-physiological endometrial changes, none of which is sufficient for the diagnosis on its
own. Previous clinical studies illustrated the reversibility of PAEC induced by UPA on endo-
metrial biopsies [3] [4]. Moreover, the occurrence of non-physiological changes of the endo-
metrium does not increase with up to 4 treatment courses and returns to pretreatment levels
within 3 months of completion of treatment, as recently reported [7].
UPA (5 mg/day, for 3 months) is currently licensed for pre-operative and intermittent
treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive
age. The effect of repeated intermittent use of UPA 5 or 10 mg daily (up to 4 courses) have
been previously studied [7]; However long term safety of up to 8 courses of treatment sepa-
rated by off treatment periods of 2 menstrual cycles, for up to 4 years of treatment and subject
follow up in total, considering the long term safety implications, is believed to be of special
interest for clinicians. Under such circumstances, UPA may be employed in women of more
advanced reproductive age approaching menopause avoiding the need for any surgery.
Materials and methods
Study design
PEARL extension 2 was an optional, long-term, open-label extension, phase III study, available
to all subjects who had previously completed 4 treatment courses with UPA 10 mg as part of
the PEARL III studies, previously published [8]. The study consisted of 4 additional 3-month
Safety of long term UPA for uterine fibroids
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courses of UPA 10 mg once daily with drug free periods of 2 spontaneous menstrual bleedings,
bringing the total number of UPA treatment courses since inclusion to 8. The treatment satis-
faction of subjects receiving repeated intermittent ulipristal acetate treatment courses was also
assessed but this report focuses on the safety aspects of the study.
This study was conducted at 16 investigation centers in four countries in Europe from July
2010 (screening) until March 2015 (last subject out). The study was approved by the indepen-
dent ethics committee of each participating site and were conducted in accordance with the
International Conference on Harmonisation-Good Clinical Practice guidelines. Names and
addresses of Central Ethics Committees by country:
Austria
Ethik-Kommission der Medizinischen Universita¨t Wien und des Allgemeinen
Krankehauses der Stadt Wien
Borschkegasse 8b/E 06
(Dienstzimmergeba¨ude, BT 68)
A–1090 Wien
Belgium
Comite´ d’Ethique Hospitalo-Facultaire Saint-Luc-UCL
AVENUE HIPPOCRATE, 55/14 Tour Harvey—Niveau 0
1200 BRUXELLES-20
Poland
Komisja Bioetyczna
przy Okręgowej Izbie Lekarskiej
ul. Świętojańska 7
15–082 Białystok
Spain
CEIC A´rea 2—Hospital Universitario de La Princesa
Cecilia Lo´pez / D.Francisco Abad
C/ Diego de Leo´n, 62
28006 Madrid
The study was designed by the sponsor (Gedeon Richter/PregLem S.A.). Clinical trial regis-
tration: ClinicalTrials.gov; NCT01642472.
Study population
Subjects enrolled in the study were women of reproductive age, with moderate to severe symp-
tomatic uterine myoma(s) with at least one fibroid 3cm in diameter and none>10cm, heavy
Safety of long term UPA for uterine fibroids
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menstrual bleeding, and uterine size <16 weeks of gestation. Eligible women were aged 18–48
years, with body mass index 18–40 (kg/m2) and regular menstrual cycles of 22–35 days with
FSH<20 IU/L. Written informed consent was obtained from all subjects.
Intervention
After finalizing treatment course 4, women could either leave the study and attend a final fol-
low-up visit 3 months later (PEARL III extension) or, enroll in this optional PEARL extension
2 study to obtain up to four further courses of UPA 10 mg, each separated by an off-treatment
period including a full menstrual cycle up to the start of the second menstruation. Screening
(baseline values) for each subject were those obtained before initiating treatment previous to
the first treatment course. Treatment course 5 was started on the first day of the first menstrua-
tion following the first visit in the study i.e. at least 3 months after the end of treatment course
4. The subsequent treatment courses 6, 7 and 8 were started on the first day of the second men-
ses after end of the previous treatment course. The follow-up visit was conducted approxi-
mately 3 months after the final treatment course.
Assessments
Endometrial histology. Endometrial biopsy samples were obtained 10–18 days after men-
struation start at screening and post-treatment courses 4 and 8, and at 3 months post-treat-
ment course 8 if required (biopsies were to be performed only if 1 or more pathologists had
provided a diagnosis other than “benign physiologic endometrium” for the biopsy after treat-
ment course 8 or if the biopsy was judged to be not adequate for histology review). The sample
collection of endometrial tissue was performed by a gynecologist using a Pipelle de Cornier.
All samples were assessed in a blinded manner by three independent pathologists experienced
in PAEC. A consensus diagnosis was considered if 2 out of the 3 pathologists were in agree-
ment of the histological assessment for each sample.
Laboratory parameters. Clinical laboratory testing (hemoglobin, creatinine, total biliru-
bin, alanine transaminase [ALT], aspartate transaminase [AST], total cholesterol, high density
lipoprotein [HDL], low density lipoprotein [LDL] and triglycerides) was analyzed in a central
clinical laboratory. Blood samples for laboratory safety examinations were collected at screen-
ing, after treatment course 4, at 3 months post-treatment course 4 and after treatment course
8. Subjects were asked to fast overnight before blood sampling for lipids were assessed. Labora-
tory results were reported and summarized using standard international units and were
assessed for clinical significance by the investigator or one of the co-investigators.
Endometrial thickness. Endometrial thickness was assessed by transvaginal ultrasound
10–18 days after start of menses following treatment courses 6 and 8 and at the 3-month fol-
low-up visit. When possible, the US was performed by the same assessor at each visit.
Statistical analysis
This study was a single-arm, open-label cohort, follow-up study and it was therefore impossi-
ble to estimate how many subjects would elect to participate in the additional 4 course (i.e. 2
years of treatment) and as such no formal statistical sample size or hypothesis testing were
planned. The main aim of the study was to accumulate extended long term safety information
and patient satisfaction with treatment, not to compare any of the results to either other treat-
ments or to historical data. As a result, no formal statistical testing and therefore p-values were
calculated for any of the parameters in the study and only descriptive statistics were created, to
allow any potential safety signals to be identified, and to ensure the patient satisfaction with
this type of long term intermittent treatment. Of the 99 subjects who had previously completed
Safety of long term UPA for uterine fibroids
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4 treatment courses, 64 subjects opted to continue in to this study. Safety analysis was con-
ducted on the Full Analysis Set (FAS). The population of primary interest was the FAS, which
was defined as all enrolled subjects who receive study medication at least once during the
study.
The statistical analysis was performed using Version 9.3 of the SAS System for Windows
([2002–2010] SAS Institute Inc).
Results
The demographic characteristics of all subjects (FAS) are provided in Table 1; demographic
data for subjects in this study were collected at baseline/screening before the first UPA treat-
ment course 1.
A total of 64 (100%), 62 (97%), 56 (88%) and 54 (84%) subjects started UPA 10 mg treat-
ment courses 5, 6, 7 and 8, respectively. A total of 11 (17%) subjects discontinued the study at
any time. The reasons for discontinuation were: lack of efficacy (N = 2), subject request
(N = 2), surgery or procedure for fibroids (N = 2), pregnancy (N = 2), adverse event (not UPA
10 mg-related) (N = 1), missing return of menstruation (N = 1) and ‘other reason’ (N = 1).
The 3-month follow-up visit after last dose of course 8 was attended by 53 (83%) subjects.
The majority of subjects who completed the study were study participants for approximately 4
years from July 2010 until March 2015. Subject disposition is shown in Fig 1. Fourteen (22%)
of the 64 subjects who continued in to this extension study started the study on the same day
as the 3-month follow-up visit post-treatment course 4. Fifty (78%) of the 64 subjects had com-
pleted treatment course 4 prior to starting this study (due to delayed study start-up), and for
these subjects the mean (median) number of days between the 3-month follow-up visit post-
treatment course 4 and the first visit in this study was 103.9 (91.0) days which translates to a
3-month longer variable off drug period.
Safety results
Endometrial thickness. The median endometrial thickness remained below that seen at
screening, with no evidence of an increase in the number of subjects with a thickness >16 mm
Table 1. Baseline demographic characteristics.
Characteristics Full Analysis Set
(N = 64)
Age (*) Mean ± SD 41.5 ± 4.8
Ethnic Origin White 60 (93.8%)
Black 3 (4.7%)
Asian 0
Hispanic 1 (1.6%)
Other 0
Weight (kg) Mean ± SD 67 ± 13.16
Body Mass Index (kg/m2) Mean ± SD 24.89 ± 4.71
(*) Age at last birthday in whole years, using the date of informed consent (PEARL III study, started in July
2010).
Note: Only month and year of birth were recorded. The 1st of the month is used for the day of birth.
Demographic data was collected at Screening / Baseline of the PEARL III study (before the first UPA
treatment course 1).
SD: Standard Deviations
doi:10.1371/journal.pone.0173523.t001
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as the number of treatment courses increased. At screening, for the 62 subjects with data avail-
able, the median endometrial thickness was 9.0 mm (range 3–21 mm), and 2 (3.2%) subjects
had thickness >16 mm. After the start of menses following treatment course 8, for the 49 sub-
jects with data available (four subjects did not perform this visit due to a delay in restart of
menstruation following the end of treatment course 8), the median endometrium thickness
was 7.0 mm (range 3–23 mm), and 1 (2.0%) subject had thickness >16 mm. At the 3-month
follow-up visit post-treatment course 8 for the 53 subjects with data available, the median
endometrial thickness remained at 7.0 mm (range 1–16 mm), and no subjects had thickness
>16 mm.
Endometrial histology. Endometrial biopsy samples were evaluated by the same 3 inde-
pendent pathologists during treatment courses 1–8. A consensus diagnosis of benign endome-
trium was made for all (100%) endometrial biopsy samples adequate for histology review,
taken from screening (96.2% adequate biopsies) through to the 3-month follow-up visit post-
treatment course 8 (91.7% adequate biopsies). Results are summarized in Table 2. All 3 indi-
vidual pathologists provided a diagnosis of benign endometrium in all evaluations with the
exception of one single individual observation of complex, non-atypical, hyperplasia reported
by one pathologist only and seen in one biopsy taken following treatment course 4. No inter-
vention was performed, and a subsequent biopsy revealed a normal endometrium confirmed
by 3 pathologists before starting course 5, which demonstrates that spontaneous resolution of
hyperplasia is in line with published literature [9] [10].
Fig 1. Flow chart of subject disposition during PEARL extension 2. Withdrawals are presented
according to the timeframes in which they occurred, either during treatment or after treatment completion for
each course.
doi:10.1371/journal.pone.0173523.g001
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PAEC. Summaries of non-physiological changes (made up of the following non-physio-
logical descriptions: epithelial changes, extensive cyst formation, unusual vascular changes
and “other” non-physiologic changes) observed by at least 2 of the 3 pathologists suggested
that after screening, when non-physiological changes were observed in 18.0% of biopsies,
the incidence in the full study population was highest in biopsies taken following treatment
course 1, seen in 35.0% of biopsies, and then subsequently decreased. Following treatment
course 4, at least 2 pathologists observed non-physiological changes in 21.4% of biopsies.
After course 8, non-physiological changes were observed in 16.3% of biopsies, which is com-
parable to baseline frequency. The majority of the non-physiological diagnosis (71.4%) was
achieved by 2 of the 3 pathologists. In all biopsies, the 3rd diagnosis (not in consensus) was
of a benign endometrium.
No additional observations were reported for biopsy samples during this study except the
presence of polyps, seen for 2 subjects prior to treatment course 5 and 2 subjects after treat-
ment course 8. Before treatment course 5, one hyperplastic polyp was diagnosed for one sub-
ject and benign polyp for one subject; for both of these a biopsy was not done after treatment
course 6, but the polyps were absent after treatment course 8. Benign polyp was diagnosed for
2 subjects after treatment course 8 but was absent at the 3-month follow-up visit.
General safety. Adverse events were collected according to standardized method prede-
fined in the study protocol. Adverse events were reported in 10 (16%), 12 (19%), 8 (14%) and 5
(9%) subjects, during treatment courses 5, 6, 7 and 8, respectively. No serious adverse events
(SAEs) were reported during this study. One subject was diagnosed as pregnant during treat-
ment course 5 and was already published [11]. One subject withdrew approximately 2 months
following the end of treatment course 7, as she chose to undergo an abdominal hysterectomy.
Overall, during treatment courses 1–8, the majority (98.4%) of all on-treatment adverse events
(AEs) were rated as being of mild or moderate intensity.
During treatment courses 1–8, the most commonly reported on-treatment AEs was head-
ache, with the greatest incidence reported by 7 (10.9%) subjects during the first treatment
course. A total of 20 (31.3%) subjects experienced at least one on-treatment AEs considered to
be UPA 10 mg-related. Overall, there was no evidence that any specific AEs increased in fre-
quency or intensity as the number of UPA 10 mg treatment courses increased, nor were any
unexpected AEs reported during this study.
Laboratory parameters. Evaluation of laboratory parameters, including changes from
screening was undertaken as part of the review of safety. No changes in the number and type
Table 2. Summary of endometrium biopsy consensus and endometrium biopsy non-physiological descriptions (PAEC) (Full analysis set, N = 64).
Screening After course 4 After Course 8 3-month after course 8
Total Biopsies 52 61 48 24
Adequate Biopsies (1*) 50 (96.2%) 56 (91.8%) 43 (89.6%) 22 (91.7%)
Benign (2**) 50 (100%) 56 (100%) 43 (100%) 22 (100%)
Hyperplasia (2**) 0 0 0 0
Malignant neoplasm (2**) 0 0 0 0
Non-physiological changes observed by two or three pathologists** 9 (18.0%) 12 (21.4%) 7 (16.3%) 2 (9.1%)
1 Endometrium biopsy performed and assessed as adequate by at least one pathologist.
2 Of those who deem specimen adequate, at least two assessors have the same opinion; otherwise the most severe is used.
* Denominator of percentage is the number of subjects that have endometrium biopsy performed.
** Denominator of percentage is the number of subjects with an adequate specimen.
doi:10.1371/journal.pone.0173523.t002
Safety of long term UPA for uterine fibroids
PLOS ONE | DOI:10.1371/journal.pone.0173523 March 7, 2017 7 / 11
of laboratory results falling outside of the normal ranges were observed as the number of treat-
ment courses increased. A summary of laboratory parameters is found in Table 3
There were no changes in vital signs, including blood pressure and one subject experienced
an unspecified increase of weight after treatment course 3.
Discussion
The objective of the study was primarily to assess the safety of intermittent treatment courses
of UPA 10 mg once daily, in women of reproductive age with symptomatic uterine fibroids
bringing the total number of treatment courses to 8. This study provides, for the first time,
evidence with regards to long term safety of UPA for the management of fibroids. Study partic-
ipation was for a mean of 46 months (range 40 to 54 months) which corresponds to approxi-
mately 4 years of treatment and follow up. The general compliance and acceptability of
treatment was high, as 83% of the subjects completed the study. In this study, only 4% of black
subjects were enrolled, however two additional phase III studies are currently being conducted
in the USA including a majority of subjects of African American origin which will allow to fur-
ther assess the safety of this treatment in this ethnic group.
In previous studies, outcomes of up to 4 repeated intermittent treatment courses have been
described [7] [8]. To date, this is the longest reported experience using a selective progesterone
receptor modulator (SPRM) in the medical management of uterine fibroids.
Progesterone receptor modulator Associated Endometrial Changes (PAEC) is a phenome-
non closely related to the use of SPRMs. It is a histological diagnosis dependent on the simulta-
neous appearance in SPRM-treated endometrium of several non-physiological changes, none
of which is specific on its own. It has been previously demonstrated that these changes are rap-
idly reversible and the frequency of PAEC returns to baseline levels after 3 spontaneous men-
strual bleeds following completion of 4 courses of 3 months each [7]. However, the potential
endometrial effects of UPA after extended repeated use was unknown.
Previous studies suggested that following treatment with UPA, an increase in endometrial
thickness from screening occurred even after one treatment course [3], but this increase subse-
quently decreased after return of menstruation following up to 4 repeated treatment courses
[7]. The extension of treatment for up to 8 courses in the present study, demonstrated that
Table 3. Summary of laboratory parameters (Full analysis set, N = 64).
Screening After course 4 3 months post treatment
course 4
After course 8
Parameter (unit), normal range N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD
Hemoglobin (g/dL), 11.5–15.5 63 12.8 ± 1.57 64 13.0 ± 1.36 63 12.8 ± 1.34 48 13.3 ± 0.95
Creatinine (umol/L), 45–84 63 61.4 ± 8.5 64 60.8 ± 8.6 63 63.0 ± 10.0 48 64.3 ± 9.8
Total bilirubin (umol/L), 0–19 63 6.5 ± 3.3 64 7.0 ± 3.6 63 7.1 ± 3.9 47 7.3 ± 3.0
AST (U/L), 0–37 63 21.3 ± 5.0 64 20.5 ± 4.5 63 21.1 ± 6.6 48 19.5 ± 4.8
ALT (U/L), 0–47 63 18.6 ± 6.7 64 16.0 ± 6.1 63 17.2 ± 10.6 48 16.8 ± 6.6
Total Cholesterol (mmol/L), 0–5.17 63 5.3 ± 0.79 60* 5.5 ± 0.82* 63 5.3 ± 0.72 49 5.3 ± 0.94
HDL (mmol/L), 1.04–25.88 63 1.7 ± 0.36 60* 1.7 ± 0.41* 63 1.7 ± 0.38 49 1.7 ± 0.35
LDL (mmol/L), 0–2.58 62 3.1 ± 0.73 60* 3.3 ± 0.79* 63 3.1 ± 0.70 49 3.1 ± 0.84
Triglycerides (mmol/L), 0–1.69 63 1.3 ± 0.88 60* 1.2 ± 0.73* 63 1.1 ± 0.70 49 1.3 ±0.82
SD: Standard Deviations
Measurements after treatment courses 4 and 8:10–18 days after the first menstruation following treatment courses 4 and 8
* Measurements in the last 2 weeks of treatment course 4
doi:10.1371/journal.pone.0173523.t003
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after return of menstruation, the endometrial thickness was lower than seen at screening for
the majority of subjects, with no evidence of increasing incidence of thickness > 16 mm.
At screening, before starting the first treatment course, non-physiological changes in endo-
metrium were observed in 18 (10.9%) subjects from the initial population enrolled in PEARL
III. Interestingly, when looking at the 64 subjects who continued to treatment courses 5 to 8,
nine (18%) subjects had non-physiological changes reported in their original assessments at
screening, so it is very likely that the higher frequency observed for the sub-group of subjects
continuing on treatment, is due to a random effect or alternatively, this could also have been
explained by a background level of non-physiological changes in their endometrium at base-
line, that is unaffected by UPA, however none of these hypothesis can be confirmed in this
study. It should be noted that non-physiological changes diminish in extent and severity after
withdrawal of UPA treatment, and the histological diagnosis of PAEC can be difficult to make
with certainty in this situation.
At the 3-month follow-up visit post-treatment course 8, biopsies were to be performed only
if 1 or more pathologists had provided a diagnosis other than “benign physiologic endome-
trium” for the biopsy after treatment course 8 or if the biopsy was judged to be not adequate
for histology review. A follow-up additional biopsy was provided by 24 subjects at the
3-month follow-up visit, and 22 biopsies were considered adequate for review. In this sub-
group, non-physiological changes were observed by at least 2 pathologists in 9.1% of biopsies
as shown in Table 2. However, taking into consideration that for more than half of all subjects
no follow-up biopsy had been requested due to a diagnosis of “benign endometrium” from all
3 pathologists after treatment course 8 (separated by one menstrual bleed after treatment end),
the observation of non-physiological changes in the full study population decreased to<5%,
returning to a level which is no different from baseline and actually numerically lower in this
study. This confirms the previously described rapid reversibility of non-physiological changes
once treatment is stopped and menstruation returns. All biopsy samples had a diagnosis of
benign endometrium by consensus review, with no cases of endometrial hyperplasia diagnosed
in the study, which gives further re-assurance on the safety of repeated administration of UPA
on the endometrial histology. Although Pipelle biopsy is not a reliable method to diagnose
endometrial polyps, only 2 small benign polyps were identified prior to treatment course 5,
and 2 after course 8. No polyps were identified on transvaginal ultrasound, and endometrial
thickness was not increased. We acknowledge the fact that in some cases, consensus was not
reached by all 3 pathologists and this should be subject of further investigation.
The frequency of on-treatment AEs observed was 31.3%; however, the most common AEs
were headache and hot flush. Considering the long duration of the study, this seems to be
acceptable. No SAEs were reported during the study.
The dose of 10 mg daily of UPA utilized in the current study was higher than the approved
dose of 5 mg/day, however the safety profile of UPA for both doses has already been evaluated
in previous studies [6].
Safety assessments including vital sign measurements, laboratory investigations, as well as
AEs demonstrated that the extended repeated administration schedule, with a drug-free inter-
val, was well tolerated and did not identify any new safety concerns.
We acknowledge the fact that this study has some limitations, such as a limited number of
subjects, lack of a comparator arm, and that this optional extension study open to subjects who
had previously completed 4 treatment courses could have biased the retention of those subjects
with a positive response to treatment; In addition, as a result no formal statistical testing and
therefore p-values were calculated for any of the parameters in the study and only descriptive
statistics were created, to allow any potential safety signals to be identified, and to ensure the
patient satisfaction with this type of long term intermittent treatment. However, none of these
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limitations were considered significant to impact the safety findings of this study which focus-
ses on the endometrial findings.
In conclusion, the current study convincingly demonstrates that the extended intermittent
administration of UPA 10 mg once daily for 3 months with drug-free intervals, bringing the
total number treatment courses undertaken to 8, is well tolerated in women of reproductive
age with symptomatic uterine myoma.
Repetition of treatment courses did not lead to any clinically relevant changes in endome-
trial histology, nor to increases in endometrial thickness. The frequency of non-physiological
changes observed did not increase with repeated treatment courses and, as previously demon-
strated, non-physiological changes were rapidly reversible.
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